Johnson Kimberly J, Brown Derek S, Thompson Tess, Barnes Justin M, King Allison A
Siteman Cancer Center, Washington University in St Louis, St. Louis, Missouri, USA.
Brown School, Washington University in St. Louis, St. Louis, Missouri, USA.
Neurooncol Pract. 2024 Oct 3;12(2):246-256. doi: 10.1093/nop/npae094. eCollection 2025 Apr.
Medicaid enrollment has been associated with disparities in younger cancer patient survival. To further understand this association for central nervous system (CNS) tumor patients, we used Surveillance, Epidemiology, and End Results (SEER)-Medicaid-linked data to examine associations between Medicaid enrollment and enrollment timing and (1) diagnosis stage, and (2) CNS tumor death.
Individuals diagnosed with a first malignant primary CNS tumor between 0 and 39 years from 2006 to 2013 were included. Medicaid enrollment was first classified as enrolled versus not enrolled with those enrolled further classified as having continuous, discontinuous (at diagnosis or other discontinuous), or other enrollment. We used logistic and Cox Proportional Hazards regression stratified by age to calculate adjusted odds ratios (ORs) and hazard ratios (HRs) for those 0-14 and 15-39 years.
Among 10 107 CNS tumor patients, we found significantly higher odds of regional/distant versus in situ/localized stage diagnoses for those with other discontinuous (OR = 1.50, 95% CI: 1.15-1.95) and at diagnosis (OR = 1.41, 95% CI: 1.11-1.78) Medicaid enrollment versus those not enrolled. Those enrolled versus not enrolled in Medicaid had a higher hazard of CNS tumor death for both age groups (HR = 1.60 95% CI: 1.37-1.86; HR = 1.50, 95% CI: 1.39-1.62) with the highest hazards for those enrolled at diagnosis (HR = 1.83, 95% CI: 1.51-2.22; HR = 1.93, 95% CI: 1.77-2.10).
Medicaid enrollment is associated with a higher risk of CNS tumor death with an almost 2-fold higher risk for young CNS tumor patients enrolled at diagnosis. These results support the critical need for consistent health insurance coverage for young CNS tumor patients.
医疗补助计划的参保情况与年轻癌症患者的生存差异有关。为了进一步了解中枢神经系统(CNS)肿瘤患者的这种关联,我们使用了监测、流行病学和最终结果(SEER)与医疗补助计划相关联的数据,来研究医疗补助计划参保情况和参保时间与(1)诊断分期,以及(2)CNS肿瘤死亡之间的关联。
纳入2006年至2013年间0至39岁被诊断为首个原发性恶性CNS肿瘤的个体。医疗补助计划参保情况首先分为参保与未参保,参保者进一步分为持续参保、间断参保(诊断时或其他间断情况)或其他参保类型。我们使用按年龄分层的逻辑回归和Cox比例风险回归,来计算0至14岁和15至39岁人群的调整优势比(OR)和风险比(HR)。
在10107例CNS肿瘤患者中,我们发现,与未参保者相比,其他间断参保(OR = 1.50,95%CI:1.15 - 1.95)和诊断时参保(OR = 1.41,95%CI:1.11 - 1.78)的患者区域/远处分期诊断的优势显著更高。两个年龄组中,参保者与未参保者相比,CNS肿瘤死亡风险更高(HR = 1.60,95%CI:1.37 - 1.86;HR = 1.50,95%CI:1.39 - 1.62),诊断时参保者风险最高(HR = 1.83,95%CI:1.51 - 2.22;HR = 1.93,95%CI:1.77 - 2.10)。
医疗补助计划参保与CNS肿瘤死亡风险较高相关,诊断时参保的年轻CNS肿瘤患者风险几乎高出两倍。这些结果支持了为年轻CNS肿瘤患者提供持续医疗保险覆盖的迫切需求。